Physician profile
Fanta Kamara
NPI 1972990612
$958.69
in general payments reported to CMS, 2019-2025
13 companies · $595 in 2025
The $595 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $363 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $193.40 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $170.51 | 2024-2025 | |
| Amgen INC. | $143.99 | 2024-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $96.12 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $70.03 | 2025 | Acthar |
| Lilly USA, LLC | $59.15 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $45.46 | 2024-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $37.54 | 2025 | Prevymis |
| Novo Nordisk INC | $31.89 | 2025 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $30.75 | 2024 | |
| Vifor Pharma, INC. | $29.20 | 2024 | Veltassa |
| Abiomed | $27.25 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.40 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fanta Kamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.